UBS upgrades Tandem Diabetes (NASDAQ:TNDM) from Neutral to Buy with a $75 target, implying a 33% upside.
The firm cites “several sources of growth” that could drive stock growth of more than 30%.
Tandem will report Q3 results on October 28 and UBS sees this as a potential positive catalyst.
TNDM shares are up 3.7% pre-market to $58.35. The company has an Outperform average Sell Side rating.
https://seekingalpha.com/news/3503985-tandem-plus-3_7-percent-ubs-leaves-sidelines
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.